Jagsonpal Pharmaceuticals Q1 Results FY27: Net Profit at Rs 13 Cr for June 2026 Quarter

Key Takeaways

• Jagsonpal Pharmaceuticals's revenue for the June 2026 quarter came in at Rs 82 Cr, rose 8.76% year on year from Rs 75 Cr.
• Jagsonpal Pharmaceuticals came in at a standalone net profit of Rs 13 Cr, up 22.18% from Rs 10 Cr in Q1 FY26.
• Gross profit was reported at Rs 15 Cr for the quarter.
• The stock traded at Rs 236.04 on 29 July 2026, up 2.40% during the session.

If you are searching for Jagsonpal Pharmaceuticals Q1 results FY27, here is the direct answer: Jagsonpal Pharmaceuticals reported standalone revenue of Rs 82 Cr and a net profit of Rs 13 Cr for the quarter ended 30 June 2026, rose 8.76% year on year from Rs 75 Cr. The rest of this article expands on that answer with the full revenue and profit breakdown, what changed compared with Q1 FY26, how the stock reacted, and what to watch next, so you do not need to piece it together from multiple sources.

Prepared by Ankit Jaiswal, Senior Research Analyst at Univest, this review of the Jagsonpal Pharmaceuticals Q1 results FY27 is based on figures disclosed in the company's exchange filing for the June 2026 quarter.

Click Here – Get Free Investment Predictions

Jagsonpal Pharmaceuticals Q1 Results FY27: Key Numbers at a Glance

Metric	Q1 FY27	Q1 FY26	YoY Change
Revenue	Rs 82 Cr	Rs 75 Cr	8.76%
Gross Profit	Rs 15 Cr	Rs 11 Cr	27.30%
Net Profit	Rs 13 Cr	Rs 10 Cr	22.18%

All figures in the Jagsonpal Pharmaceuticals Q1 results FY27 table above are on a standalone basis for the quarter ended 30 June 2026, compared with Q1 FY26. This is the core data set behind the Jagsonpal Pharmaceuticals Q1 results FY27 search.

Jagsonpal Pharmaceuticals Q1 Results FY27: What Drove Revenue

Revenue for Jagsonpal Pharmaceuticals in Q1 FY27 rose 8.76% from Rs 75 Cr to Rs 82 Cr, against Rs 75 Cr in Q1 FY26. Anyone comparing Jagsonpal Pharmaceuticals against its own past performance should treat this as the base number: a company in the pharmaceutical formulations space, this pace of growth reflects demand and pricing trends specific to that segment during the June 2026 quarter.

Jagsonpal Pharmaceuticals Q1 Results FY27: Profitability Breakdown

Jagsonpal Pharmaceuticals came in at a standalone net profit of Rs 13 Cr, up 22.18% from Rs 10 Cr in Q1 FY26 in Q1 FY27. Gross profit for the quarter was Rs 15 Cr, a change of 27.30% from Rs 11 Cr in Q1 FY26.

The broadly consistent movement between gross profit and net profit in the Jagsonpal Pharmaceuticals Q1 results FY27 suggests the quarter's profit performance is being driven mainly by core operations rather than one-off or below-the-line items.

Stock Price Reaction to the Jagsonpal Pharmaceuticals Q1 Results FY27

Jagsonpal Pharmaceuticals shares traded at Rs 236.04 on 29 July 2026, up 2.40% during the session. If your search intent is specifically about the stock reaction rather than the raw numbers, this is the figure that answers it: the market's verdict weighed the revenue and profit results together, alongside broader market conditions on the day.

Talk to a SEBI Registered Investment Adviser Before You Invest

What the Jagsonpal Pharmaceuticals Q1 Results FY27 Mean for Investors

The Jagsonpal Pharmaceuticals Q1 results FY27 give investors three concrete data points: a revenue base of Rs 82 Cr, a net profit of Rs 13 Cr, and a year-on-year growth trajectory that either confirms or challenges the investment thesis for the stock. None of these numbers should be read in isolation from the detailed exchange filing, segment disclosures and management commentary that typically accompany results.

Comparing this quarter with peers in the pharmaceutical formulations space is also useful context. A company can post strong absolute growth and still lag its peer set, or post modest growth that is nonetheless best-in-class for its sector, so relative positioning matters as much as the standalone numbers in the Jagsonpal Pharmaceuticals Q1 results FY27. Investors who track a basket of names in the same industry will typically get a clearer read on whether this quarter reflects a company-specific story or a broader sector trend.

Business Context Behind the Jagsonpal Pharmaceuticals Q1 Results FY27

Jagsonpal Pharmaceuticals operates in the pharmaceutical formulations space, where demand cycles, input costs and competitive intensity all shape quarterly performance. The Jagsonpal Pharmaceuticals Q1 results FY27 should be read against these sector-level dynamics rather than as a standalone number, since the same growth rate can carry very different implications depending on the underlying industry conditions.

Quarterly results are unaudited and subject to limited review, so any restatements or exceptional items disclosed in the notes to the Jagsonpal Pharmaceuticals Q1 results FY27 can shift how the reported profit should be interpreted. Reading the full exchange filing alongside this summary remains the most reliable way to form a complete view, particularly for line items such as other income, exceptional items and tax adjustments that do not always show up in a headline summary.

Key Things to Watch After the Jagsonpal Pharmaceuticals Q1 Results FY27

• Sequential trend: Whether the momentum in the Jagsonpal Pharmaceuticals Q1 results FY27 carries into the September 2026 quarter or proves to be a one-off.
• Management commentary: Guidance on demand, margins and capital allocation for the rest of FY27.
• Sector conditions: Developments in the pharmaceutical formulations space that could influence input costs, pricing power or competitive intensity.
• Corporate actions: Any dividend, capex or strategic announcements accompanying the results that signal management's confidence in the outlook.
• Balance sheet health: Debt levels, working capital trends and cash flow generation, which together determine how much flexibility Jagsonpal Pharmaceuticals has to fund future growth.

Download the Univest iOS App or Univest Android App to track quarterly results, live prices and research updates in one place.

Conclusion

The Jagsonpal Pharmaceuticals Q1 results FY27 show standalone revenue of Rs 82 Cr and a net profit of Rs 13 Cr for the quarter ended 30 June 2026. The quarter's profit delivery keeps the near-term earnings narrative broadly intact. As Ankit Jaiswal notes, investors should track the next few quarterly prints and management commentary before drawing firm conclusions, and consult a SEBI registered investment adviser before acting on these results.

FAQs on Jagsonpal Pharmaceuticals Q1 Results FY27

What was Jagsonpal Pharmaceuticals's revenue in Q1 results FY27?

Ans. Jagsonpal Pharmaceuticals's revenue in Q1 results FY27 was Rs 82 Cr, rose 8.76% year on year from Rs 75 Cr.

Did Jagsonpal Pharmaceuticals make a profit or loss in Q1 FY27?

Ans. Jagsonpal Pharmaceuticals reported a net profit of Rs 13 Cr in Q1 results FY27 on a standalone basis for the quarter ended 30 June 2026.

What was Jagsonpal Pharmaceuticals's gross profit in Q1 FY27?

Ans. Jagsonpal Pharmaceuticals's gross profit in Q1 results FY27 was Rs 15 Cr, against Rs 11 Cr in Q1 FY26.

When were the Jagsonpal Pharmaceuticals Q1 results FY27 announced?

Ans. The Jagsonpal Pharmaceuticals Q1 results FY27 were announced on 29 July 2026, covering the quarter ended 30 June 2026.

Did Jagsonpal Pharmaceuticals shares go up or down after the Q1 results FY27?

Ans. Jagsonpal Pharmaceuticals shares traded at Rs 236.04 on 29 July 2026, up 2.40% following the Q1 results FY27.

Were the Jagsonpal Pharmaceuticals Q1 results FY27 consolidated or standalone?

Ans. The Jagsonpal Pharmaceuticals Q1 results FY27 are on a standalone basis, as reported in the company's exchange filing for the June 2026 quarter.

What should investors watch after Jagsonpal Pharmaceuticals's Q1 results FY27?

Ans. Investors should watch the sequential trend into the September quarter, management commentary, sector-level conditions in the pharmaceutical formulations space, and any corporate action announcements.

Are the Jagsonpal Pharmaceuticals Q1 results FY27 a buy signal?

Ans. Quarterly results are a data point, not a recommendation. Investors should assess valuations, earnings quality and their own risk profile, and consult a SEBI registered investment adviser before investing.